Essential Medical Inc. Announces FDA Approval to Begin a U.S. Clinical Trial for the Manta Large Bore Vascular Closure Device
MALVERN, Pennsylvania, July 8, 2016 -- Essential Medical, Inc., a privately held medical device company addressing the rapidly growing large bore vascular closure market, announced today that it has received Investigational Device Exemption (IDE) approval from the FDA to begin the U.S. clinical trial for MANTA, the company's Large Bore Vascular Closure Device.
The pivotal study will evaluate the safety and efficacy of vascular access closure using MANTA for femoral arterial access sites in patients undergoing percutaneous procedures using sheaths ranging from 10F to 24F. MANTA will be used to achieve safe, percutaneous closure in a variety of large bore procedures including transfemoral transcatheter aortic valve replacement (TAVR), endovascular aortic repair (EVAR) of abdominal aortic aneurysms (AAA), ventricular assist devices (VAD), and balloon aortic valvuloplasty (BAV).
These large bore procedures are the fastest growing segment of the cardiovascular market and are driving a worldwide market for large bore vascular closure devices to exceed $600 million within the next 5 years. Closure of large bore femoral access sites has been associated with significant increases in morbidity including longer times to achieve hemostasis, extended procedure time, higher rate of complications, and higher total cost of care. MANTA was specifically designed to address these complexities of closing large punctures in high-pressure vessels utilizing novel closure technology. MANTA's simple and fail-safe deployment provides immediate hemostasis in order to reduce the complications and cost associated with large bore closure.
Dr. David Wood, Co-Principal Investigator of the US MANTA trial and a founding member of the Centre for Heart Valve Innovation in Vancouver Canada, stated "We are constantly seeking a safer and more efficient way to replace a patient's failing heart valve, which is why our ongoing Multidisciplinary, Multimodality, but Minimalist (3M) TAVR Trial is so important. While transfemoral TAVR has advanced rapidly and can now be safely performed in fully awake patients in less than 30 minutes, the vascular closure method for these cases has not progressed and access site related complications remain a concern. Safe, reproducible percutaneous large bore closure is needed before transfemoral TAVR can become the default strategy in most patients."
Dr. Zvonimir Krajcer, Co-Principal Investigator of the US MANTA trial and Co-Director, Peripheral Vascular Disease Service at the Texas Heart Institute in Houston, commented "I'm very excited to be a part of the MANTA vascular closure trial as I believe it will deliver fewer complications and faster overall procedure times based on the EU data. Until now for EVAR, TEVAR and TAVAR we had to use the vascular closure devices that were not originally designed for this indication. Finally, for the first time with MANTA we will have the opportunity to use a reliable and simple vascular closure device for large bore sheaths. This device will in a safer way advance the treatment of many patients with aortic aneurysmal and valvular heart disease."
About Essential Medical
Essential Medical, Inc., is a privately held company focused on transforming the large bore vascular closure market by delivering products that meet the unmet need for fast closure without complications. The company was founded in 2010 by Greg Walters, a senior product development executive with 20 years' experience creating innovative cardiovascular products, and Dr. Gary Roubin, MD, PhD, a coronary and carotid stenting pioneer.